Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 16, 2025Journal of Antimicrobial ChemotherapyOpen Access

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKirby Patterson-FahyRCRobyn CarterSBScott C. Bell

Discussion

Loading...

Member takes

Overview

In vitro testing shows sulbactam/durlobactam increases antibiotic susceptibility in Mycobacterium abscessus, suggesting better treatment options.

Key Points

  • To assess if sulbactam/durlobactam enhances β-lactam antibiotic susceptibility in Mycobacterium abscessus isolates.
  • Conducted antibiotic susceptibility testing for sulbactam/durlobactam and β-lactam antibiotics.
  • Compared susceptibility results against imipenem and relebactam.
  • Utilized different culture media for measuring MICs.
  • Sulbactam/durlobactam significantly lowered MICs for meropenem and cefuroxime/amoxicillin.
  • Culture medium impacted MIC results, with Middlebrook 7H9 showing lower MICs for combinations.
  • Confirmed durlobactam's role in increasing susceptibility to β-lactam antibiotics in Mycobacterium abscessus.

Cite This Study

Patterson-Fahy et al. (2025) studied this question.

synapsesocial.com/papers/6940acc83507a57a7f7a44dahttps://doi.org/10.1093/jac/dkaf441
View Full Paper
Ask AI
Bookmark
Share